Tags

Type your tag names separated by a space and hit enter

Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease.
Neuroscience. 2019 08 10; 413:308-316.N

Abstract

Parkinson's disease (PD) is a common movement disorder. Alpha-synuclein (α-synuclein) plays a critical role in PD. In this study, we evaluated the level of central nervous system (CNS)-derived exosomal α-synuclein in serum, which may be regarded as a specific peripheral biomarker for PD. We recruited patients with PD in the early stage along with essential tremor (ET), and we recruited age- and gender-matched healthy subjects as healthy controls (HC). We divided patients with PD into the tremor-dominant (TD) group and the non-tremor-dominant (NTD) group. We evaluated the levels of α-synuclein in CNS-derived exosomes in serum samples. As a result, there was a significant difference between four groups (p<0.05). This level was lower in the PD group than in the ET and HC groups (p<0.05). Among the PD group, this level was lower in the NTD group than in the TD group (p<0.05). Furthermore, the performance of serum CNS-derived exosomal α-synuclein was found to moderately aid in PD diagnosis (AUC=0.675, p<0.05) and had a potential to diagnose NTD (AUC=0.761, p<0.05). Therefore, CNS-derived exosomal α-synuclein in the serum may be regarded as a biomarker to identify PD from ET and HC in the early stage. It may also be used to identify different motor types in PD. The pathogenesis of PD in different motor types may be different, which needs further research.

Authors+Show Affiliations

Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Department of Neurology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Electronic address: jialipu@zju.edu.cn.Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Electronic address: brzhang@zju.edu.cn.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31102760

Citation

Si, Xiaoli, et al. "Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease." Neuroscience, vol. 413, 2019, pp. 308-316.
Si X, Tian J, Chen Y, et al. Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease. Neuroscience. 2019;413:308-316.
Si, X., Tian, J., Chen, Y., Yan, Y., Pu, J., & Zhang, B. (2019). Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease. Neuroscience, 413, 308-316. https://doi.org/10.1016/j.neuroscience.2019.05.015
Si X, et al. Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease. Neuroscience. 2019 08 10;413:308-316. PubMed PMID: 31102760.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease. AU - Si,Xiaoli, AU - Tian,Jun, AU - Chen,Yanxing, AU - Yan,Yaping, AU - Pu,Jiali, AU - Zhang,Baorong, Y1 - 2019/05/16/ PY - 2018/10/12/received PY - 2019/05/02/revised PY - 2019/05/03/accepted PY - 2019/5/19/pubmed PY - 2020/3/10/medline PY - 2019/5/19/entrez KW - Parkinson’s disease KW - alpha-synuclein KW - biomarker KW - essential tremor KW - exosome SP - 308 EP - 316 JF - Neuroscience JO - Neuroscience VL - 413 N2 - Parkinson's disease (PD) is a common movement disorder. Alpha-synuclein (α-synuclein) plays a critical role in PD. In this study, we evaluated the level of central nervous system (CNS)-derived exosomal α-synuclein in serum, which may be regarded as a specific peripheral biomarker for PD. We recruited patients with PD in the early stage along with essential tremor (ET), and we recruited age- and gender-matched healthy subjects as healthy controls (HC). We divided patients with PD into the tremor-dominant (TD) group and the non-tremor-dominant (NTD) group. We evaluated the levels of α-synuclein in CNS-derived exosomes in serum samples. As a result, there was a significant difference between four groups (p<0.05). This level was lower in the PD group than in the ET and HC groups (p<0.05). Among the PD group, this level was lower in the NTD group than in the TD group (p<0.05). Furthermore, the performance of serum CNS-derived exosomal α-synuclein was found to moderately aid in PD diagnosis (AUC=0.675, p<0.05) and had a potential to diagnose NTD (AUC=0.761, p<0.05). Therefore, CNS-derived exosomal α-synuclein in the serum may be regarded as a biomarker to identify PD from ET and HC in the early stage. It may also be used to identify different motor types in PD. The pathogenesis of PD in different motor types may be different, which needs further research. SN - 1873-7544 UR - https://www.unboundmedicine.com/medline/citation/31102760/Central_Nervous_System_Derived_Exosomal_Alpha_Synuclein_in_Serum_May_Be_a_Biomarker_in_Parkinson's_Disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0306-4522(19)30331-8 DB - PRIME DP - Unbound Medicine ER -